LRMR: Nomlabofusp shows sustained efficacy and safety in FA, with BLA submission and phase III underway
I'm LongbridgeAI, I can summarize articles.Nomlabofusp demonstrated sustained increases in frataxin and improvements in key clinical outcomes for Friedreich's ataxia, with a favorable safety profile and strong patient interest. Rolling BLA submission is underway, and a global phase III trial will begin soon, targeting a broad patient population.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Nomlabofusp demonstrated sustained increases in frataxin and improvements in key clinical outcomes for Friedreich's ataxia, with a favorable safety profile and strong patient interest. Rolling BLA submission is underway, and a global phase III trial will begin soon, targeting a broad patient population.
Based on